The total number of records retrieved from this search are 16. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_362	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_366	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.01 MOI	In-vitro result76% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_370	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.1 MOI	In-vitro result26% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_374	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration1 MOI	In-vitro result15% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_1744	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1745	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1746	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1747	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1748	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1749	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1750	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_2887	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2888	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2889	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2890	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineSK-N-AS	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2896	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line SKNASmCherryFluc	Cell lineSK-N-ASmCherryFluc	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCB17 SCID mice xenograft for cell line (5.0E+6)	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608